New methods to treat a specific type of ovarian cancer
Official title: New Approaches to Modeling and Targeting Cyclin E-amplified High-Grade Serous Tubo-Ovarian Carcinoma
Funded at New York University School of Medicine · NIH-11001564 · Data updated 2026-11-12
This study is looking at a tough type of ovarian cancer called high-grade serous tubo-ovarian carcinoma to find out why it often doesn't respond to regular treatments, and it's testing new therapy combinations to help improve outcomes for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | December 10, 2020 |
| Project end | November 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $703,320 |
| NIH project number | 5R01CA257507-05 |
| Project ID | NIH-11001564 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with high-grade serous tubo-ovarian carcinoma, particularly those with CCNE1 amplification.
✕Less likely to help
Patients with other types of ovarian cancer or those who are not platinum-resistant may not benefit from this research.
What this research studies
This research focuses on high-grade serous tubo-ovarian carcinoma (HGSC), a form of ovarian cancer that often resists standard treatments. The team is developing advanced models to better understand the genetic factors that contribute to this resistance, particularly the amplification of the CCNE1 gene. By creating organoid models that mimic human cancer, they aim to test new combinations of therapies, including chemotherapy and immunotherapy, to improve treatment outcomes for patients with this aggressive cancer. The research involves collaboration among experts in cancer biology and genomics to ensure a comprehensive approach to tackling this challenging disease.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with platinum-resistant ovarian cancer.
How similar studies have gone: Other research has shown promise in using organoid models to study cancer, indicating that this approach could yield valuable insights.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Neel, Benjamin G. — New York University School of Medicine
- Study coordinator: Neel, Benjamin G.
Related research
Other NIH-funded projects on the same topics.
-
Using imaging data to predict outcomes in ovarian cancer patients
This study is looking at how regular CT scans can be used to find important clues that help predict how well women with a specific type of ovarian cancer might do after treatment, so doctors can make better choices for their care.
-
Hippo/YAP pathway in aggressive ovarian cancer
Researchers aim to find out how a cell-control system called Hippo/YAP helps start and drive the most deadly form of ovarian cancer in women.
-
Blocking CDK7 as a new approach for aggressive ovarian cancer
This work explores whether blocking a protein called CDK7 can help treat women with high-grade serous ovarian cancer, especially tumors with CDK7 loss or BRCA-related DNA repair problems.
-
A new CAR T cell therapy targeting ovarian cancer
This study is testing a new type of CAR T cell therapy for women with ovarian cancer that uses special immune cells to better target the cancer and includes a safety feature to help protect patients from side effects.
-
Combining trametinib and navitoclax to treat recurrent ovarian cancer
This study is testing a new combination treatment for women with recurrent ovarian cancer that hasn't responded to standard therapies, aiming to see if it can help improve their outcomes.
-
Targeting a specific protein to treat advanced ovarian cancer
This study is looking at a new way to help people with advanced ovarian cancer by targeting a specific protein that helps cancer cells survive, hoping to make current treatments work better for those who have few options left.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.